福泰製藥股票討論區

$福泰製藥(VRTX.US)$
NEWS
Vertex Pharmaceuticals Inc expected to post earnings of $4.06 a share - Earnings Preview
Vertex Pharmaceuticals Inc VRTX.OQ VRTX.O is expected to show a rise in quarterly revenue when it reports results on May 6 for the period ending March 31 2024
The Boston Massachusetts-based company is expected to report a 8.6% increase in revenue to $2.579 billion from $2.37 billion a year ago, according to the mean estimate from 23 analysts, based on LSEG data.
​LSEG's...

$福泰製藥(VRTX.US)$
NEWS
Vertex Pharmaceuticals Inc - Treefrog Will Also Receive up to $215M in Milestones

$福泰製藥(VRTX.US)$
NEWS
Vertex Pharmaceuticals Inc - Under Agreement, Treefrog Will Receive a $25M Upfront Payment, an Equity Investment From Vertex
Vertex Will Fund All Research and Development Costs Related to Collaboration

$福泰製藥(VRTX.US)$
NEWS
Vertex and Treefrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes

$諾瓦瓦克斯醫藥(NVAX.US)$
Novavax 2024：引領市場的疫苗巨頭準備再次震撼世界
隨着2024年的腳步日益臨近，生物科技界的翹楚Novavax正站在新的里程碑前。去年，這家生物科技巨頭啓動了一場前所未有的公司轉型，準備在股市上掀起一場風暴。隨着研發（R&D）和銷售、總務及行政（SG&A）費用的大幅削減，Novavax不僅展示了其財務紀律的鋼鐵意志，而且彰顯了其在全球疫苗市場的領導地位。
財務重塑，劍指未來
在2023年，Novavax宣佈了震撼行業的消息：將其運營成本削減至不可思議的7.5億美元以下。這一戰略決定不僅將公司塑造成爲一個更加精幹高效的戰鬥機器，還預示着其在2024年的股票市場上的強勁表現。公司的高層領導，包括敢於想象的總裁兼首席執行官John C. Jacobs，正帶領Novavax走向前所未有的高峰。
疫苗市場的終極破局者
作爲全球疫苗市場的創新領軍者，Novavax不滿足於現狀。公司的COVID-19與流感聯合疫苗的第三階段試驗即將啓動，預計將爲全球提供前...

$諾瓦瓦克斯醫藥(NVAX.US)$
Novavax 2024年：期待股價的顯著表現
隨着全球經濟逐漸從疫情中恢復，生物技術公司Novavax正在通過一系列戰略轉型措施，準備迎接2024年的市場挑戰。2023年，該公司啓動了一項重大轉型計劃，包括顯著減少研發（R&D）和銷售、總務及行政（SG&A）開支的目標。通過這些戰略調整，Novavax不僅優化了其財務狀況，而且加強了其在優先市場交付差異化COVID-19疫苗的能力，同時加速了COVID-19與流感聯合疫苗的研發進程。
財務表現和結構優化
Novavax在2023年第三季度業績電話會議上宣佈，公司計劃在2024年將研發及銷售、總務及行政開支控制在7.5億美元以下。此舉是爲了加強公司的財務狀況並聚焦於核心競爭力的提升。同時，公司還宣佈將全球員工總數減少約12%，預計完成後，公司的員工總數將比2023年第一季度末減少約30%。這一決策反映了公司追求更精簡、更靈活的運營模式的戰略方向。
市場機遇與未來展望
John C. Jacobs, Novavax的總裁...

$諾瓦瓦克斯醫藥(NVAX.US)$$Moderna(MRNA.US)$
April 18, 2024
For Global Investor Audience Only
Novavax’s Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) is now available to pharmacies across the United Kingdom (U.K.) for private healthcare providers to offer an updated protein-based non-mRNA option as part of the 2024 vaccination season.  
To...

$ProKidney(PROK.US)$ sank more than 15% Thursday as the biotech snapped a five-session winning streak that saw its price rise some 130% in just days.
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...

$ProKidney(PROK.US)$ rose more than 30% Tuesday as the biotech firm rallied for the fourth straight session – a run-up that's seen the stock rise nearly 90% in less than a week.
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $福泰製藥(VRTX.US)$ unveiled plans to buy biotech $Alpine Immune(ALPN.US)$ for $4.9 ...

$耐克(NKE.US)$$福泰製藥(VRTX.US)$$萬事達(MA.US)$$Visa(V.US)$$愛彼迎(ABNB.US)$
📊⚡️📊